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Summary
 
RAS
 
 mutations arise at high frequency (20–40%) in both acute myeloid leukemia and myelod-
ysplastic syndrome (which is considered to be a manifestation of preleukemic disease). In each
case, mutations arise predominantly at the 
 
N-RAS
 
 locus. These observations suggest a funda-
mental role for this oncogene in leukemogenesis. However, despite its obvious significance, lit-
tle is known of how this key oncogene may subvert the process of hematopoiesis in human
cells. Using CD34
 
1
 
 progenitor cells, we have modeled the preleukemic state by infecting these
cells with amphotropic retrovirus expressing mutant 
 
N-RAS
 
 together with the selectable
marker gene 
 
lacZ.
 
 Expression of the 
 
lacZ
 
 gene product, 
 
b
 
-galactosidase, allows direct identifi-
cation and study of 
 
N-RAS
 
–expressing cells by incubating infected cultures with a fluorogenic
substrate for 
 
b
 
-galactosidase, which gives rise to a fluorescent signal within the infected cells.
By using multiparameter flow cytometry, we have studied the ability of CD34
 
1
 
 cells expressing
mutant 
 
N-RAS
 
 to undergo erythroid differentiation induced by erythropoietin. By this means,
we have found that erythroid progenitor cells expressing mutant 
 
N-RAS
 
 exhibit a proliferative
defect resulting in an increased cell doubling time and a decrease in the proportion of cells in S 
 
1
 
G2M phase of the cell cycle. This is linked to a slowing in the rate of differentiation as deter-
mined by comparative cell-surface marker analysis and ultimate failure of the differentiation
program at the late-erythroblast stage of development. The dyserythropoiesis was also linked to
an increased tendency of the 
 
RAS
 
-expressing cells to undergo programmed cell death during
their differentiation program. This erythroid lineage dysplasia recapitulates one of the most
common features of myelodysplastic syndrome, and for the first time provides a causative link
between mutational activation of 
 
N-RAS
 
 and the pathogenesis of preleukemia.
 
R
 
AS 
 
proto-oncogenes (1) are a group of closely related
genes (
 
H-RAS
 
, 
 
K-RAS
 
, and 
 
N-RAS
 
) that encode 21-
kD proteins, which function as molecular switches in signal
transduction. RAS proteins transduce downstream signals
when in the GTP-bound conformation, but are inactive
when bound GTP is hydrolyzed to GDP by an intrinsic
GTPase activity. A variety of extracellular stimuli result in
the formation of RAS-GTP, in particular, many cytokines
result in activation of 
 
RAS
 
 through stimulation of receptor
tyrosine kinase activity (2, 3). Downstream signals are me-
diated through a number of target molecules including
RAF kinases PI-3 kinase and MEK kinase-1, which have the
ability to stimulate a wide array of biological responses
from proliferation to cell death (4).
Before its significance as a signal transducer became
known, 
 
RAS
 
 genes were identified as important onco-
genes, occurring at high frequency across a wide range of
malignancies (5). 
 
RAS
 
 oncogenes have mutations around
codons 12 or 60 that result in proteins with greatly reduced
GTPase activity and hence, proteins that are constitutively
active signal transducers. Mutational activation of RAS
genes is one of the most common abnormalities associated
with hematological malignancy. The highest incidence in
leukemia occurs in acute myeloid leukemia where 
 
z
 
30%
of patients have activated 
 
RAS
 
 genes (5). Mutations occur
in 
 
N-RAS
 
 (mainly) or 
 
K-RAS
 
, whereas 
 
H-RAS
 
 mutations
are rarely detected. A similar frequency of 
 
RAS
 
 mutations
are found in preleukemic syndromes, the incidence in my-
elodysplastic patients being in the range of 25–45% (6).
60% of these mutations involve G to A transitions at codon
12 or 13 of 
 
N-RAS
 
, which usually results in the substitu-
tion of glycine for aspartic acid (7). In addition to mutation,
other mechanisms of constitutive activation of RAS are
also associated with hematological malignancy: constitutive
upstream signals, e.g., from BCR-ABL (8); loss of negative
regulator function, e.g., in neurofibromatosis patients (9);
and overexpression of RAS which is common both in leu-
kemia and preleukemia (10, 11).
The presence of high frequencies of 
 
RAS
 
 abnormalities
in hematological malignancy, together with its role in growth
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factor signaling, provides abundant correlative evidence
that 
 
RAS
 
 oncogenes play an important role in leukemo-
genesis. In addition, their prevalence in myelodysplasia also
suggests that constitutive activation of RAS plays a role
early in leukemogenesis. Myelodysplatic patients exhibit
disorders of development of one or more of the hemato-
poietic lineages, although the erythroid lineage is most
commonly affected (12–14). The disorder is clonal in ori-
gin and probably results from a defect at the stem cell level
(15, 16). There is, however, little causative evidence that
oncogenic 
 
RAS
 
 can disrupt normal hematopoiesis and give
rise to the changes which are manifest in leukemia and
preleukemia. To investigate the possible role of this onco-
gene as an initiating event in leukemogenesis, we have ex-
amined whether mutant 
 
N-RAS
 
 alone can affect the devel-
opment potential of human progenitor cells. To study these
cells throughout their development, we have used retrovi-
ral constructs expressing the reporter gene 
 
lacZ
 
 to identify
single CD34
 
1
 
 cells expressing an 
 
N-RAS
 
 oncogene, and
followed their subsequent differentiation and proliferation in
response to erythropoietin (EPO)
 
1
 
 by using multiparameter
flow cytometry. We show here, for the first time, that ex-
pression of mutant 
 
N-RAS
 
 in primary hematopoietic pro-
genitor cells severely impairs their subsequent ability to un-
dergo erythroid development.
 
Materials and Methods
 
Retroviral Vectors and Producer Lines.
 
The retroviral vectors were
based on the myeloproliferative sarcoma virus (MPSV). MPSV
containing the selectable marker 
 
lacZ
 
 was constructed by blunt
cloning the bacterial 
 
lacZ
 
 gene as BamH1 fragment of pGH101
(ATCC 37480; American Type Culture Collection, Rockville,
MD) into the 
 
env
 
 position of the MPSV plasmid pM7J (gift of Carol
Stocking, Heinrich Pette Institute, Hamburg, Germany). Full-
length human 
 
N-RAS
 
 cDNA (containing a mutation in codon 12
resulting in glycine being substituted for aspartic acid) was excised
with HindIII from GC61 (gift of Alan Hall, University College,
London, U.K.). This was introduced by a second round of blunt
cloning into the 
 
gag/pol
 
 position to create the double gene vector.
The integrity of the construct DNA was checked by sequence
analysis around the cloning sites. Retrovirus was generated by ex-
pressing these constructs in the ecotropic packaging line GP
 
1
 
E86
(gift of Dina Markovitz, Columbia University, New York). Virus
from these cells was subsequently used to infect the correspond-
ing amphotropic producer line GP
 
1
 
env
 
AM12. High titre ampho-
tropic producer clones, 154-3 (MPSV–
 
lacZ
 
) and 181-7 (MPSV–
 
N-RAS-lacZ
 
), were then selected, which gave titres of 1–5 
 
3
 
 10
 
5
 
infectious units per milliliter. Packaging lines were negative for
helper virus as judged by the absence of transmissible virus from
pure infected cultures of NIH3T3 and K562 cells (see below) and
by the absence of amphotropic 
 
env
 
 sequences after PCR of DNA
from these cell lines using the 
 
env
 
-specific primers described pre-
viously (17).
 
Cell Culture and Infection.
 
The protocol described below in-
volves a two-stage culture of CD34
 
1
 
 cells. First, these cells were
cultured in the absence of EPO, including a period of co-cultiva-
tion with retroviral producer cells to allow infection to occur. Sec-
ond, after enrichment of the infected cells, EPO was added to
stimulate erythroid differentiation. This protocol is similar to one
already described (18) and allows all stages of EPO-dependent
erythroid maturation to be studied.
CD34
 
1
 
 cells were purified from mononuclear cells from neo-
natal cord blood using MiniMACS (Miltenyi Biotec, Camberley,
U.K.) according to the manufacturer’s instructions. These prepa-
rations were 
 
.
 
95% CD34
 
1
 
. These cells were subsequently cul-
tured at 2 
 
3
 
 10
 
5
 
 cells/ml in IMDM containing 1% deionized bo-
vine serum albumin fraction V (Sigma Chemical Co., Poole,
U.K.), 20% FCS, 4.5 
 
3
 
 10
 
2
 
5
 
M 
 
b
 
-mercaptoethanol, 360 
 
m
 
g/ml
of 30% iron-saturated human transferrin (Boehringer Mannheim
Biochemical, Lewes, U.K.), 25 ng/ml IL-3, 50 ng/ml IL-6
(R&D Sys. Inc., Minneapolis, MN), and 50 ng/ml stem cell fac-
tor (SCF) (gift of Amgen Biologicals, Thousand Oaks, CA). After
40 h culture, these cells were seeded at 2 
 
3
 
 10
 
5
 
 cells/ml onto
preestablished monolayers of producer cells: 154-3, 181-7, and
parental GP
 
1
 
env
 
AM12. This gave rise to control-, 
 
N-RAS
 
– and
mock-infected cultures, respectively. Co-cultivation was carried
out for 48 h in the presence of 4 
 
m
 
g/ml polybrene with an equal
volume of fresh medium (as above) being added after 24 h. Non-
adherent cells were then harvested and cultured in fresh medium
for a further 48 h. These cells were then stained for 
 
b
 
-galactosi-
dase expression and infected cells enriched to 50–60% purity (as
described below). After enrichment, cells were cultured at 2 
 
3
 
10
 
5
 
 cells/ml in IMDM as above but containing 5 ng/ml IL-3, 10
ng/ml IL-6, 20 ng/ml SCF, and 2 U/ml EPO (Boehringer Mann-
heim Biochemical). A subsequent culture was carried out in the
same medium. Cell densities were maintained at 0.2–1.0 
 
3
 
 10
 
6
 
cells/ml. In some experiments, enriched cells were introduced
into semisolid medium to assess colony formation as previously
described (19). The concentration of growth factors for erythroid
colony formation were as above. To assess granulocyte macrophage
colony formation, granulocyte macrophage colony stimulating fac-
tor (5 ng/ml) was added in place of EPO.
To assess retroviral expression of 
 
N-RAS
 
 and to check for the
absence of helper virus, the above retroviral producer lines were
used to infect NIH3T3 and K562 cells. K562 cells were grown in
RPMI medium containing 10% FCS and were infected by co-
cultivation as described above. Infection frequency of this cell line
was 15–20%. NIH3T3 cells were grown in DMEM containing
10% newborn calf serum and were infected by exposure to 0.4-
 
m
 
m
filtered retroviral supernatant. In each case, pure cultures of retro-
virally infected cells were derived by carrying out two rounds of
cell sorting for 
 
b
 
-galactosidase positive cells as described below.
 
Cell Labeling and Flow Cytometry.
 
For cell sorting and all anal-
yses except for cell cycle analysis, cells were initially stained for
 
b
 
-galactosidase expression as previously described (20). In brief,
cells in culture medium were mixed with an equal volume of a 2
mM aqueous solution of the fluorogenic substrate, fluorescein di
 
b
 
-galactoside (FDG; Molecular Probes Inc., Eugene, OR) at 37
 
8
 
C
for 60 s. Substrate loading was then stopped by adding a 20-fold
excess of isotonic medium at 4
 
8
 
C. Substrate-loaded cells were
then incubated for 16 h at 4
 
8
 
C before sorting or further labeling.
Cells expressing 
 
b
 
-galactosidase hydrolyze the nonfluorescent sub-
strate, FDG, into the fluorescent compound fluorescein, which is
retained within the cell at 4
 
8
 
C.
For fluorescence-activated cell sorting of cells directly after in-
fection, cells were stained with FDG and propidium iodide (PI) at
 
1
 
Abbreviations used in this paper:
 
 7AAD, 7-amino actinomycin D; EPO,
erythropoietin; FDG, fluorescein di 
 
b
 
-galactosidase; gly A, glycophorin
A; MPSV, myeloproliferative sarcoma virus; PI, propidium iodide; PS,
phosphatidyl serine; R, receptor; SCF, stem cell factor; tc, cell cycle time. 
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1 
 
m
 
g/ml to stain membrane-damaged cells. Viable, PI negative,
fluorescein-bright cells (5–10% of total) were enriched by using a
FACS
 
Ò
 
 440 (Becton Dickinson, San Jose, CA) using standard fil-
ters for PI and fluorescein. The cells were kept ice-cold during this
procedure. Stained, mock-infected cells were used to define the
level of background fluorescence. Cells sorted for morphological
assessment were sorted in the same way, except that yield was sac-
rificed to give purities of 
 
.
 
85%. Sorted cells were subsequently
kept on ice before cytospin preparation. Cells were stained with a
modified Wright-Giemsa stain (Bayer, Newbury, U.K.). Cells clearly
demonstrating a condensed nucleus were scored as apoptotic (see
Fig. 10).
For immunophenotyping, cells were subsequently kept ice-cold
and stained with phycoerythrin-labeled monoclonal antibodies di-
rected against the following antigens: CD34(clone 8G12), HLA-
DR (L243), CD13 (L138), CD33 (P67.6) (all from Becton Dick-
inson), glycophorin A (D2.10; Immunotech, Marseille, France), and
CD71 (RVS-10; Cymbus Bioscience, Southampton, U.K.). CD36
(FA6-152; Immunotech) was indirectly stained using anti–mouse
phycoerythrin-labeled second antibody (DAKO, High Wycombe,
U.K.). All stains were controlled with an appropriate isotype-
matched control reagent. Each incubation was carried out for 30
min on ice with antibodies being applied at the recommended
concentrations. After staining, cells were resuspended in ice-cold
medium containing 1 
 
m
 
g/ml 7-amino actinomycin D (7AAD;
Molecular Probes, Inc.). Cells were analyzed on a FACScan
 
Ò
 
 cy-
tometer equipped with a single argon ion laser.
Cell cycle analysis was carried out by supravitally staining cul-
tures with Hoechst 33342 (Molecular Probes, Inc.) at 5 
 
m
 
g/ml for
60 min under normal culture conditions. Cells were subsequently
stained for 
 
b
 
-galactosidase activity as described above. PI at 1 
 
m
 
g/ml
was used to identify membrane-damaged cells. Cells were ana-
lyzed on a FACS
 
Ò
 
 440 dual laser cytometer. PI and Hoechst were
excited by UV radiation and analyzed at 630 and 424 nm. Fluo-
rescein was excited at 488 nm and analyzed at 513 nm. PI fluores-
cence from 488 excitation was excluded by temporal separation.
To determine the frequency of apoptotic cells within these cul-
tures, cells stained for 
 
b
 
-galactosidase activity were resuspended
in DMEM and incubated on ice with biotinylated annexin V (Nex-
ins Research, Hoeven, Netherlands) for 10 min at the recom-
mended concentration. These cells were then washed and incu-
bated with streptavidin phycoerythrin (DAKO) for 30 min on
ice. After staining, cells were resuspended in ice-cold medium
containing 1 
 
m
 
g/ml 7AAD and analyzed using a FACScan
 
Ò
 
 cy-
tometer.
 
Data Analysis.
 
Acquired data were analyzed using Lysys II
(Becton Dickinson) and WinMDI (gift of Joe Trotter, Scripps In-
stitute, La Jolla, CA). Cell cycle analysis was carried out using the
pragmatic approach of Watson et al. (21). Copies can be obtained
from CytonetUK http://www.cf.ac.uk/uwcm/hg/hoy/. Infected
cultures contained mixed populations of infected and uninfected
cells. Infected cells were identified as those exhibiting greater flu-
orescence than the equivalent mock-infected culture (see Fig. 2).
The threshold of positivity was set such that 
 
.
 
90% of the selected
cells had fluorescence greater than the mock-infected control.
Membrane-damaged cells were excluded from the analysis on the
basis of strong staining with 7AAD or PI as appropriate. In this
way, both infected and uninfected populations were analyzed by
gating on 
 
b
 
-galactosidase positive and negative cells, respectively.
Analysis of the frequency of retroviral expression in control-
and 
 
RAS-infected cells (see Fig. 3) was restricted to the erythro-
blast population by applying a forward scatter threshold; this was
to eliminate loss of lacZ expression due to terminal differentiation
(and enucleation) of control-infected cells. The percentage of cells
demonstrating positive labeling for cell-surface markers was cal-
culated by setting a threshold (.95% of cells) on equivalently
gated cells stained with an isotype-matched control antibody. The
percentage of cells demonstrating positive labeling for annexin V
was calculated by setting a threshold (.99% of cells) on equival-
ently gated cells stained with streptavidin phycoerythrin only. In
analysis of cell cycle data, the relative time spent in G1 and S 1
G2M was estimated on the basis that relative frequency of cells
was proportional to the time spent in these phases; this assumes
that all cells in the culture were cycling. Since analysis of the
RAS-expressing cells showed only a relative increase in G1 phase,
the increment in cell cycle time was calculated on the basis that
time spent in synthesis and division was unaltered. Significance of
difference was tested using the paired t test.
Northern Analysis. To demonstrate coexpression of mutant
N-RAS in hematopoietic cells infected with MPSV–N-RAS-lacZ
retrovirus, total RNA from pure cultures of K562 cells expressing
MPSV–N-RAS-lacZ were isolated using RNAzol (AMS Biotech-
nology, Witney, U.K.) according to the manufacturer’s instruc-
tions. 20 mg of RNA was then loaded onto a 1% agarose formal-
dehyde gel. RNA from K562 cells infected with lacZ alone and
181-7 packaging line RNA were also loaded as controls. North-
ern blotting was carried out as previously described (22). The
HindIII fragment of GC61 (see above) was used as a probe for
N-RAS mRNA. The same membrane was subsequently reprobed
with b-actin (Oncor Inc., Gaithersburg, MD). Fig. 1 demonstrates
that K562 cells infected with MPSV-N-RAS-lacZ express moder-
ate levels of N-RAS mRNA in comparison to the packaging line
control. Due to the antiproliferative effect of mutant N-RAS on
primary erythroblasts (see Results), we were unable to generate
sufficient material to carry out Northern analysis to determine the
average level of transduced N-RAS expression in these cultures.
Results
Expression of Mutant N-RAS in Erythroid Progenitors Induces
an Antiproliferative Effect. Fig. 2 illustrates b-galactosidase
expression in control cells (expressing lacZ alone) and in
RAS-infected cells (coexpressing mutant N-RAS and lacZ).
By applying a threshold of positivity defined by an identically
treated mock-infected culture, we were able to assess the
relative proportion of infected cells in the culture. This en-
abled us to determine the relative expansion of the infected
cells in relation to the uninfected cells throughout the sub-
sequent culture period. Fig. 3 demonstrates that the relative
expansion of control-infected erythroblasts was close to
that of uninfected cells, demonstrating that there was stable
expression of b-galactosidase in these cells and that expres-
Figure 1. Northern analysis of
N-RAS expression. Lane 1, 181-7
packaging line (positive con-
trol); lane 2, K562-lacZ cells;
lane  3, K562-N-RAS-lacZ cells.
The upper panel demonstrates
the expression of the lacZ-N-RAS
transcript of the expected size.
The lower panel shows the same
blot reprobed with b-actin.1340 Mutant N-RAS Induces Erythroid Dysplasia in Human CD341 Cells
sion of this selectable marker did not overtly affect their
proliferative capacity. On the other hand, the proportion of
RAS-infected erythroblasts rapidly declined, indicating that
the effect of activated RAS on these cells was to reduce
their overall proliferative rate in comparison with the non-
expressing cells within the same culture. This rate of de-
cline appeared to be constant, since logarithmic transforma-
tion of these data yielded a linear plot (r 5 20.9982). This
allowed us to calculate that the effective doubling time of
these cells was increased from 14.6 to 18.9 h, a 29% aver-
age increase over the time frame indicated. The cumulative
effects of this increase resulted in the gradual disappearance
of RAS-expressing cells from these cultures. A number of
explanations could account for this observation: (a) cell cy-
cle time (tc) is increased, (b) cell cycle is unaffected, but there
is an increased rate of premature cell death, or (c) a combi-
nation of the above. To determine whether expression of
mutant N-RAS caused perturbation of the normal cell cy-
cle distribution, we supravitally stained these cultures for
DNA content in combination with staining for b-galactosi-
dase activity. Fig. 4 shows that the proportion of cells in cy-
cle was indeed reduced in the RAS-expressing cells (43%)
when compared with the control-infected cells (59%); P
,0.001. Since these cultures contained mixed populations
of infected and uninfected cells (as defined by b-galactosi-
dase positivity), we were also able to analyze the cells not
expressing mutant RAS within the same culture; this analy-
sis effectively acts as an internal control. The proportion of
cells in cycle in this population (57%) was effectively iden-
tical to the controls and demonstrates that the changes in
cell cycle distribution were specific to the mutant RAS-
expressing cells within the culture. The most likely expla-
nation for the observed decrease in the proportion of cells
in S 1 G2M is that, on average, the RAS-expressing cells
spent more time in the G1 phase of the cell cycle. If this is
the case, the increased proportion in G1 could be accounted
for by an overall increase in tc of 30% to 19 h. This value is
close to the actual increased doubling time observed above
and suggests that increase in cell cycle time alone could ac-
count for the decreased proliferative rate of these cells.
Mutant N-RAS–expressing Erythroblasts Show an Increased
Tendency to Apoptose. Since it has been reported that pre-
mature cell death by apoptosis is a feature of preleukemia
(23–25), we investigated whether expression of mutant
N-RAS had any effect on the tendency of erythroid cells to
undergo apoptosis. The extent of apoptosis cannot be im-
plied from cell cycle data (Fig. 4) since erythroid cells do
not necessarily enter G0 before apoptosis (26). To circum-
Figure 2. Expression of b-galactosidase after infection of CD341 cells.
Mock-infected cells (open histograms) indicate the threshold for positi-
vity. These data represent b-galactosidase expression after a 3 d induction
with EPO.
Figure 3. Relative expansion of b-galactosidase positive cells after in-
duction with EPO. The data have been normalized relative to expression
after a 3 d induction with EPO. The mean of six separate experiments is
shown; error bars indicate 6 SD.
Figure 4. Effect of mutant N-RAS expression on cell cycle distribu-
tion. Representative histograms are shown from one of four experiments.
Filled histograms represent infected cells (b-galactosidase positive); open
histograms show uninfected cells (b-galactosidase negative) within the
same culture. Values indicate the proportion of cells in S 1 G2M 6 SD.
**P ,0.001.1341 Darley et al.
vent this, we measured one of the earliest events associated
with the apoptotic program, exposure of phosphatidyl
serine (PS) at the cell surface using the PS probe, annexin V
(27–30). This allows simultaneous identification of infected
(b-galactosidase-positive) cells and estimation of the fre-
quency of apoptosis. Fig. 5 demonstrates that after 5 d of
culture with EPO, the frequency of apoptosis in RAS-
expressing cells was 1.7 times that detected in control-infected
cells or in the uninfected cells within the same culture. Es-
sentially identical results were obtained when these cultures
were reanalyzed by this technique after 7 d (not shown). To
confirm this result, we sorted lacZ-positive cells from both
cultures and scored apoptotic frequency by morphological
assessment. Again, the RAS-infected cells showed signifi-
cantly enhanced levels of apoptosis (1.8 times the control).
The overall levels of apoptosis were somewhat lower than
indicated by using annexin V; however, this is probably ac-
counted for by the fact that exposure of PS on the cell sur-
face precedes the overt morphological changes associated
with apoptosis (31).
Despite this enhanced level of programmed cell death,
the overall proportion of apoptotic cells in the culture was
too low to suggest that it greatly contributed to the reduced
proliferative capacity of the RAS-expressing cells. These data
support the fact that the most important antiproliferative
effect of RAS appears to be mediated through increase in
tc, most probably as a result of extension of G1.
Expression of Mutant N-RAS in CD341 Cells Causes Aber-
rant Display of Developmental Markers. The abnormalities in
the proliferative status of mutant RAS-expressing erythroid
cells led us to examine whether their developmental capac-
ity was also affected. By following changes in cell-surface
marker expression in these cultures, it is possible to moni-
tor the differentiated status of these cells (32–35). Fig. 6
shows the phenotype of infected cells before induction of
differentiation with erythropoietin. These data demonstrate
that after infection, the cultures are predominantly CD341
HLA-DR1 CD331 which is characteristic of a mixed pro-
genitor population. Approximately 50% of these cells were
erythroid committed as defined by expression of a throm-
bospondin receptor (CD36). As would be expected from
these EPO-deprived cultures, these cells were glycophorin
A (gly A) negative (not shown). Expression of transferrin
receptor CD71 was heterogeneous, with the majority of
cells expressing intermediate levels of CD71. After 5 d of
exposure to EPO, these cultures were morphologically and
phenotypically (CD361 and CD132) almost exclusively ery-
throid as a result of relative expansion of this population
under the influence of EPO (18). Fig. 7 shows that control-
infected cultures exhibited a loss or marked downregulation
of cell-surface markers associated with primitive erythroid
cells, i.e., were CD342 (not shown) and HLA-DRlo. Expres-
sion of CD33 also declines rapidly during early erythroid de-
velopment (32), and this was also observed. At the same time,
upregulation of markers associated with erythroid develop-
ment occurred, with approximately half of the cells ex-
pressing gly A and nearly all cells expressing high levels of
transferrin receptor CD71. This pattern of expression was
essentially identical to mock-infected cells, demonstrating
that retroviral infection and expression of b-galactosidase in
these cells had not affected their ability to differentiate.
In contrast, cells expressing the N-RAS oncogene dem-
onstrated reduced or absent expression of gly A. CD71 ex-
pression was also abnormal in that a large proportion of the
cells apparently failed to upregulate expression of transferrin
receptor to the levels seen on control cells. In addition,
markers associated with more immature cells were retained,
with the RAS-transduced cells expressing significantly higher
levels of HLA-DR and CD33. The absence of CD341 ex-
pression on these cells, however, suggested that the early
stages of differentiation had taken place. Again, these pheno-
typic abnormalities were specific to the mutant RAS-express-
ing cells, since the phenotype of the nonexpressing cells within
Figure 5. Frequency of apoptotic cells. (A) Frequency as defined by
staining with annexin V. Infected and uninfected cells within each culture
were separately analyzed; only RAS-expressing cells showed enhanced
frequency of apoptotic cells (**P ,0.001). (B) Frequency as defined by
morphological assessment of infected cells (*P ,0.05). In each case, the
mean of four experiments is shown; error bars indicate 6 SD.
Figure 6. Immunophenotypic analysis of cells before induction of dif-
ferentiation with EPO. Representative histograms from one of four ex-
periments are shown. Dashed histograms represent levels of control anti-
body staining. Mean percentage expression of each marker 6 SD are
indicated.1342 Mutant N-RAS Induces Erythroid Dysplasia in Human CD341 Cells
the same culture was not significantly different than that of
the controls.
Overall, these results suggest a block or attenuation in
the capacity of these RAS-expressing cells to undergo ery-
throid differentiation. One possible explanation for these
results is that the differentiation the RAS-expressing cells
was merely delayed as a result of their increased doubling
time. Since, on this basis, RAS-expressing cells could po-
tentially have undergone two fewer divisions after 5 d of
culture, we reanalyzed these cells after a further 48 h cul-
ture period. The results in Fig. 8 demonstrate that whereas
expression of some markers (HLA-DR, CD33, gly A) re-
covered to the levels of day 5 control cells, other markers
associated with erythroid differentiation remained aberrant;
in particular, a large proportion of cells had still failed to
upregulate CD71 expression to normal levels (P ,0.05).
Interestingly, this extra culture period was also associated
with a significant decrease in expression of CD36 when
compared to both days 5 and 7 control cells (P ,0.05).
Declining CD36 expression is a feature of the more ad-
vanced stages of erythroid maturation (34); therefore, in the
context of this marker, RAS-expressing cells could be in-
terpreted as being more mature than control cells. Thus,
even taking into account a delay in differentiation (perhaps
as a result of increased cell cycle time), the immunopheno-
type of the RAS-expressing erythroid cells remained aber-
rant.
Mutant N-RAS–expressing CD341 Cells Fail to Develop
into Late Erythroblasts. To investigate whether, despite their
phenotypic abnormalities, RAS-expressing erythroid cells
can give rise to normal progeny by morphological criteria,
we isolated b-galactosidase–positive cells by FACSÒ and
compared the morphology of the control- and RAS-infected
cells. Although by day 8 of induction with EPO, control
cultures were already rich in mature progeny (not shown),
we isolated infected cells after 10 d of culture to allow for a
possible developmental delay of the RAS-expressing cells.
Figs. 9 and 10 show that the control-infected cells exhib-
ited a range of differentiated morphology, including late
erythroblasts, after 10 d of culture. In contrast, virtually no
Figure 7. Effect of mutant
N-RAS expression on cell-sur-
face markers. Representative his-
tograms from one of at least four
experiments are shown for each
marker. Dashed histograms rep-
resent levels of control antibody
staining. Mean percentage ex-
pression of each marker 6 SD,
or in the case of CD71 and CD36,
mean fluorescence intensity 6 SD
are indicated. *significant differ-
ence P ,0.05, **P ,0.001.
Figure 8. Immunophenotype of RAS-expressing cells compared with
control values after 5- and 7-d induction with EPO. Open symbols,
RAS-expressing cells after 5-d induction; closed symbols, RAS-express-
ing cells after 7-d induction. Expression levels have been normalized to
that of control cells after 5-d induction with EPO (100%). Data are based
on mean percentage expression in the case of HLA-DR, CD33, and gly
A and mean fluorescence intensity in the case of CD71 and CD36. Means
of at least three experiments are shown for each marker; error bars indi-
cate SD.1343 Darley et al.
late erythroblast morphology was observed in the RAS-
expressing population, indicating that even after prolonged
culture, these cells are unable to generate viable late eryth-
roblasts. In support of these data, we found that erythroid
colony formation from cultures containing RAS-infected
cells was consistently reduced (53% of control, P ,0.001,
n 5 5) whereas there was no significant difference in gran-
ulocyte macrophage colony formation (P 5 0.89). Given
that these cultures were only 50–60% enriched for infected
cells, it suggests a complete failure of erythroid colony for-
mation under clonal conditions.
Discussion
We have studied the effect of an N-RAS oncogene as a
single abnormality during erythroid differentiation. Perhaps
the most surprising finding of this study is the antiprolifera-
tive effect induced by expression of mutant N-RAS. This
was observed both as a decrease in the relative rate of pro-
liferation and by a reduced proportion of cells in S phase
relative to control cultures. This phenotype is at odds with
the positive effect of mutant RAS expression on prolifera-
tion and alleviation of growth factor dependence indicated
from work on hematopoietic cell lines (36, 37). However,
these data are consistent with cell cycle analysis of more ad-
vanced stage myelodysplastic patients, which demonstrate
reduced rates of cell cycle progression in the erythroid
compartment (38–40). These data are also consistent with
the reduced erythroid output observed in all subtypes of
myelodysplasia (12–14). Recent evidence suggests, that re-
duced erythroid output in preleukemia patients may partly
result from a block in precursor formation (41, 42) suggest-
ing either that lineage decision making is affected, or that
erythroid differentiation is blocked at a very early stage.
From the results of this study, we cannot exclude the possi-
bility that mutant RAS also affects lineage decision making,
since the target population in this study consisted primarily
of cells which were already lineage committed.
As might be expected, the antiproliferative effect was
combined with developmental changes. This was observed
both in the context of morphology and immunophenotyp-
ing data. Immunophenotypically, RAS-expressing cells tended
to retain markers of relatively immature erythroid cells (CD33,
HLA-DR) while expression of markers associated with later
erythroid development (gly A) were largely absent. To some
extent, this appeared to result from a delayed differentiation
program since the aforementioned markers recovered to
near normal levels after a further 48 h culture. This in itself
would not be expected to yield abnormal progeny, since
there appears to be a degree of flexibility in the cellular dy-
namics of erythroid development (43). However, not all
markers attained normal levels of expression; transferrin re-
ceptor (CD71) expression remained low throughout the
culture period and thrombospondin receptor (CD36) be-
came aberrant in day 7 cultures. It is tempting to suggest
that low CD71 expression may be a further manifestation
of the reduced proliferative activity of these cells; however,
CD71 expression is regulated differently in erythroid com-
pared with nonerythroid cells, and there is no relationship
between CD71 expression and proliferative status, particu-
larly during the later stages of development (35, 44). More
significantly, there is an absolute requirement for transferrin
for normal development for erythroid cells (44). Therefore,
the abnormal regulation of CD71 may, in part, explain their
subsequent failure to complete differentiation. Morpholog-
ical analysis demonstrated that even after extended culture,
RAS-expressing erythroid cells were unable to generate vi-
able late erythroblasts. The block in development was also
supported by colony formation data. Thus the antiprolifer-
ative effect of mutant N-RAS appears to be combined with
an ultimate block in differentiation.
The consequences of such a block depend on the subse-
quent fate of the expressing cell; either the cell could con-
tinue to proliferate without further differentiation, or the
failure to successfully complete the differentiation program
would trigger apoptosis. We found no evidence of contin-
ued proliferation of RAS-expressing erythroid cells within
these cultures. However, we were able to demonstrate an
increased frequency of apoptotic cells within the RAS-
expressing population. Overall, these data suggest that mu-
tant  N-RAS–expressing erythroblasts undergo apoptosis
rather than complete erythroid differentiation. This sce-
nario again has parallels in the pathogenesis of preleukemia,
where a number of investigators have recently reported in-
creased frequencies of apoptotic cells in myelodysplastic
marrow (23–25).
Decreased cell proliferation combined with increased fre-
quency of apoptosis suggests an impairment of signaling
from growth factor receptors. EPO is known to be impor-
tant in driving proliferation and preventing apoptosis (45–47),
while SCF has a synergistic effect on erythroid output (48);
indeed SCF receptor (R) may directly stimulate EPO-R
(49). However, using specific monoclonal antibodies to
Figure 9. Differential counts of erythroid morphology. RAS-infected
cells (solid bars) and control-infected cells (open bars). Data show the mean
of two experiments; error bars indicate 6 SD. * significant difference P
,0.05.1344 Mutant N-RAS Induces Erythroid Dysplasia in Human CD341 Cells
Figure 10. Morphology of RAS-expressing erythroid cells. (A) Control-infected cells purified by cell sorting, (B–C) corresponding RAS-infected cells.
PE, proerythroblast; IE, intermediate erythroblast; LE, late erythroblast; AP, apoptotic cell. Original magnification, 31000.1345 Darley et al.
EPO-R and SCF-R, we have found no reduction in the
level of receptor expression on the RAS-expressing cells
(data not shown). Loss of expression of EPO-R and SCF-R,
likewise does not explain the reduced responsiveness of
preleukemia cells to these growth factors (50).
The most likely interpretation of these results is that con-
stitutive activation of N-RAS transduces an antiprolifera-
tive signal in erythroblasts, and there is indirect evidence to
support this. The role of RAS in growth factor receptor
signaling has been dissected by creating COOH-terminal–
deleted receptor molecules which fail to activate RAS. Such
mutations of EPO-R expressed in cell lines have failed to
demonstrate any mitogenic role of RAS in EPO-R signal-
ing (51). Moreover, genetically acquired COOH-trunca-
tions of EPO-R lead to erythrocytosis and hypersensitivity
to EPO (52). These data are therefore consistent with the
results presented here, namely, that constitutive activation
of RAS does not mediate a mitogenic signal for erythro-
blasts. Indeed, our results suggest that constitutively activated
RAS antagonizes both the mitogenic effects of EPO and its
ability to protect against apoptosis. A potential mechanism
by which activated RAS could mediate such an effect may
involve the phosphotyrosine phosphatase, SHP-1. SHP-1
has been shown to dephosphorylate EPO-activated JAK2,
and this is thought to be important for the downmodula-
tion of signals generated by activated EPO-R (53). Since it
has also been demonstrated that SHP-1 can become acti-
vated in a RAS-GTP–dependent manner (54), there is a
possible link between activation of RAS and suppression of
cytokine signaling. Such a mechanism is also supported by
the observation that inactivating mutations of SHP-1 as
found in “motheaten” mice (55) result in hypersensitivity
to EPO (56).
In contrast, the ability of mutant RAS to block erythroid
maturation does not appear to involve changes to EPO sig-
naling per se, since we have recently shown that RAS onco-
genes also inhibit erythroid development in erythroleuke-
mia cells, which differentiate in response to low molecular
weight inducers (Zaker, F., R.L. Darley, and A.K. Burnett,
manuscript submitted). It is also unlikely that RAS-express-
ing erythroid cells secreted a factor that antagonized their
development such as TGF-b (57) or TNF-a (58), since the
nonexpressing cells within the same culture proliferated
and differentiated normally (although such a factor acting at
an exclusively autocrine level cannot be ruled out). On the
other hand, mutant N-RAS may affect the activity of ery-
throid transcription factors as does inappropriate expression
of the Evi-1 gene. This gene is activated by translocations
which are found at low frequency in both leukemia and
preleukemia (59–61). Expression of this gene in cells with
erythroid potential blocks their development through a mech-
anism which appears to involve repression of the transcrip-
tional properties of GATA-1 (62).
The effects of mutant RAS expression in erythroid cells
provide an interesting counterpoint to its effect on mono-
cytic differentiation. A number of hematopoietic cell lines
undergo spontaneous monocytic differentiation in response
to mutant RAS expression (37, 63; Darley, R.L., unpub-
lished observations) and transgenic mouse experiments also
indicate an important role for the RAS protooncogene in
monocytic development (64). Furthermore, antisense ex-
periments have shown that N-RAS expression is required
for monocytopoiesis, but is not required throughout eryth-
roid differentiation of human CD341 cells (65); therefore,
RAS may play fundamentally different roles in the devel-
opment of these lineages.
In conclusion, the failure to generate functionally mature
hematopoietic cells is a key feature of leukemia and preleu-
kemia. These results demonstrate that activation of N-RAS
alone is capable of eliciting such a change. Furthermore,
from a number of aspects, these changes mimic the pathol-
ogy of preleukemia and therefore, for the first time, pro-
vide a causative link between the activation of N-RAS and
the pathogenesis of this disease. Finally, we have also dem-
onstrated the feasibility of studying, in detail, the effects of
a retrovirally introduced transgene in single human progen-
itor cells and in their differentiated progeny. We hope that
this methodology will help to further our understanding of
the role of RAS and other putative oncogenes in leukemo-
genesis.
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